The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood plasma derivatives market was valued at US$ 40.5 Billion in 2021.
We expect the global blood plasma derivatives market to exhibit a CAGR of 6.40% during 2022-2027.
Extensive R&D activities for understanding the potency of blood plasma products in several therapeutic treatments, including immunology, oncology, pulmonology, rheumatology, neurology, etc., are primarily driving the global blood plasma derivatives market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of blood plasma derivatives to treat the patients suffering from the coronavirus infection, thereby positively influencing the market growth.
Based on the type, the global blood plasma derivatives market has been segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Among these, immunoglobulin currently holds the majority of the total market share.
Based on the end-user, the global blood plasma derivatives market can be divided into hospitals, clinics, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global blood plasma derivatives market include Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at